Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
McGill University
$27,000.00
Scavenger Receptor Antagonists for Peritoneal Adhesions
FY 2025-26
Summary
In up to 90% of patients who underwent abdominal surgery, separate regions in the peritoneum can be connected through scar tissue adhesions leading to chronic pain, infertility, etc. The only FDA approved treatments are three preventative physical barrier devices with questionable efficacy. There’s a lack of therapeutics targeting the molecular mechanism behind such a common surgical complication. Recently, Dr. Paul Kubes and his lab revealed that specific peritoneal macrophages undergo a platelet-like aggregation that leads to these adhesions. Two expressed cell-surface scavenger receptors, MSR1 and MARCO, were shown to be required for the key aggregation step. Through competitive antagonism of an unidentified native ligand, polyinosinic acid (PolyI) inhibited the formation of post-operative adhesions both in vitro and in vivo. In collaboration with Dr. Kubes, the Castagner group showed that other polyanionic macromolecules inhibit macrophage aggregation in vitro. We hypothesize that negatively charged compounds designed with the receptor’s geometry and trimeric structure in mind could prove to be effective inhibitors. We plan to synthesize anionic macromolecules that vary in structure, charge, as well as size. Candidates will then be assayed through the same in vitro and in vivo methods established by our collaborators. successful candidate inhibitors will then be modified to improve their residence time in the peritoneal cavity. This could yield an effective and novel preventative treatment for this frequent post-operative complication.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572546
Name
Slilaty David E
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Scavenger Receptor Antagonists for Peritoneal Adhesions
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Antagonist; Drug Discovery; Macrophage; Peritoneal Adhesions; Polyelectrolytes; Scavenger Receptors
Abstract
In up to 90% of patients who underwent abdominal surgery, separate regions in the peritoneum can be connected through scar tissue adhesions leading to chronic pain, infertility, etc. The only FDA approved treatments are three preventative physical barrier devices with questionable efficacy. There’s a lack of therapeutics targeting the molecular mechanism behind such a common surgical complication. Recently, Dr. Paul Kubes and his lab revealed that specific peritoneal macrophages undergo a platelet-like aggregation that leads to these adhesions. Two expressed cell-surface scavenger receptors, MSR1 and MARCO, were shown to be required for the key aggregation step. Through competitive antagonism of an unidentified native ligand, polyinosinic acid (PolyI) inhibited the formation of post-operative adhesions both in vitro and in vivo. In collaboration with Dr. Kubes, the Castagner group showed that other polyanionic macromolecules inhibit macrophage aggregation in vitro. We hypothesize that negatively charged compounds designed with the receptor’s geometry and trimeric structure in mind could prove to be effective inhibitors. We plan to synthesize anionic macromolecules that vary in structure, charge, as well as size. Candidates will then be assayed through the same in vitro and in vivo methods established by our collaborators. successful candidate inhibitors will then be modified to improve their residence time in the peritoneal cavity. This could yield an effective and novel preventative treatment for this frequent post-operative complication.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Slilaty, David E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~